It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic diseases, as it pays $200 million for rights to preclinical-stage ...

Denmark's Novo Nordisk said on Tuesday it had submitted a new, higher dose of its obesity treatment Wegovy to the European ...

Novo Nordisk submits a higher 7.2 mg dose of Wegovy for EMA approval, backed by trials showing 21% weight loss in obesity and ...

Italian authorities on Monday appointed a special commissioner to help Danish drugmaker Novo Nordisk speedily deliver its ...

Discover why Novo Nordisk's current sell-off offers a strong buy opportunity. Backed by solid fundamentals, growth prospects, ...

Analysts said the deal with Novo was likely giving Hims “‘credibility’ or increased consumer traffic,” adding that the ...

Review the current Novo Nordisk AS ADR (NVO:XNYS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if NVO is the best investment for you.

Septerna’s Native Complex platform is the engine that will make this happen. Septerna Inc. 250 East Grand Avenue South San Francisco, California 1 650 338-3533 ...

Novo Nordisk Inks A Major Obesity Deal, Sending Shares Of New Partner Septerna Skyrocketing Investor's Business Daily • last month ...

Historical Prices for Novo Nordisk A/S (B Shares) ADRhedged Jun. 07 2025 Jul. 07 2025 Download Reset ... Price change over selected period: -10.81% -4.46 ...